CTOs on the Move


 
Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Vizgen raised $14M on 01/30/2020
Vizgen raised $85.2M on 06/03/2022

Similar Companies

Newlight Technologies

Newlight Technologies is a company based in Irvine, California known for carbon sequestration into plastics.

Curran Biotech

Curran Biotech is a materials manufacturing company that provides nano coatings to biochemical, chemical, energy and construction industries including water-repellent coatings for fabrics, canvas, tarps, and glass. Our hydrophobic coatings are specifically designed to improve the nature and quality of the substrates by preventing water-substrate interactions. The technology was developed in the materials/chemistry labs (Institute for Nano Energy) of the physics department at the University of Houston and started commercialization in 2013.

Virtual Incision

Virtual Incision Corporation is a privately-held medical device company focused on developing an advanced, miniaturized robot for general surgery abdominal procedures, such as colon resections. Propelled by the knowledge that colorectal and lower gastrointestinal procedures are the fastest growing in the United States, Dr. Dmitry Oleynikov and Dr. Shane Farritor founded Virtual Incision in 2006. The company is a spin-out of the University of Nebraska, where Dr. Dmitry Oleynikov and Dr. Shane Farritor are currently based. John Murphy joined Virtual Incision in 2012 and is based in Pleasanton, California.

Ciitizen

Ciitizen is a platform that helps you collect, organize, and share your medical records digitally. Use it to get a second opinion, coordinate with a caregiver, and donate to research.

Just. Biotherapeutics

Just. is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. We believe that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.